Literature DB >> 33070576

Paraneoplastic autoimmune multiorgan syndrome.

Dario Didona1, Giovanni DI Zenzo2, Pascal Joly3.   

Abstract

Originally described by Anhalt as paraneoplastic pemphigus in 1990, paraneoplastic autoimmune multiorgan syndrome (PAMS) is a potentially lethal blistering disease, characterized by polymorphous clinical features, including mucocutaneous erosions, blisters, lichenoid papules, and erythemas. Several autoantibodies have been detected in serum of PAMS patients, including antiplakins, anti-alpha-2-macroglobulin like 1, and antidesmogleins autoantibodies. The mortality rate of PAMS is up to 90%. This is due on the one hand to the poor response to treatments and on the other hand to the delay in the diagnosis and to the prognosis of the underlying neoplasia.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33070576     DOI: 10.23736/S2784-8671.20.06675-4

Source DB:  PubMed          Journal:  Ital J Dermatol Venerol        ISSN: 2784-8671


  5 in total

1.  [Paraneoplastic skin syndromes].

Authors:  Amir S Yazdi; Michael Hertl
Journal:  Hautarzt       Date:  2021-04-01       Impact factor: 0.751

Review 2.  Paraneoplastic syndrome in neuroophthalmology.

Authors:  Longdan Kang; Chao Wan
Journal:  J Neurol       Date:  2022-07-02       Impact factor: 6.682

Review 3.  Plectin in Skin Fragility Disorders.

Authors:  Dimitra Kiritsi; Leonidas Tsakiris; Franziska Schauer
Journal:  Cells       Date:  2021-10-14       Impact factor: 6.600

Review 4.  Pemphigus Vulgaris: Present and Future Therapeutic Strategies.

Authors:  Dario Didona; Giovanni Paolino; Giovanni Di Zenzo; Biagio Didona; Riccardo Pampena; Matteo Riccardo Di Nicola; Santo Raffaele Mercuri
Journal:  Dermatol Pract Concept       Date:  2022-01-01

5.  Antibody-Negative Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS) in a Patient with Follicular Lymphoma Accompanied by an Excess of Peripheral Blood CD8+ Lymphocytes.

Authors:  Thilo Gambichler; Yi-Pei Lee; Ilske Oschlies; Christina H Scheel; Wolfram Klapper; Nico Nowack; Martin Doerler; Markus Stücker; Nasreddin Abolmaali; Laura Susok
Journal:  Curr Oncol       Date:  2022-03-28       Impact factor: 3.109

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.